Search company, investor...
ArthroSurface company logo

ArthroSurface

arthrosurface.com

Founded Year

2002

Stage

Acquired | Acquired

Total Raised

$33.8M

Valuation

$0000 

About ArthroSurface

Arthrosurface, Inc. was organized to develop surgical alternatives for the treatment of orthopedic joint disease. Per the company, Arthrosurface's initial efforts have resulted in the development of a new method to repair isolated articular cartilage defects and damage to major joints including the knees, hips and shoulders using minimal access surgical procedures.

Headquarters Location

28 Forge Parkway

Franklin, Massachusetts, 02038,

United States

508-520-3003

Missing: ArthroSurface's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ArthroSurface's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ArthroSurface

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ArthroSurface is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

ArthroSurface Patents

ArthroSurface has filed 1 patent.

The 3 most popular patent topics include:

  • Orthopedic surgical procedures
  • Skeletal system
  • Joints
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/19/2019

10/25/2022

Joints, Skeletal system, Orthopedic surgical procedures, Bone fractures, Upper limb anatomy

Grant

Application Date

11/19/2019

Grant Date

10/25/2022

Title

Related Topics

Joints, Skeletal system, Orthopedic surgical procedures, Bone fractures, Upper limb anatomy

Status

Grant

Latest ArthroSurface News

Shoulder arthroplasty with inlay glenoid component linked with improved outcomes

Jun 19, 2020

Disclosures: Nicholson reports he receives royalties from Wright Medical Technology; is a paid consultant for Tornier and Wright Medical Technology; receives research support from Arthrex; receives fellowship education support from Smith & Nephew; is a paid presenter for Arthrosurface; and serves on the board of the American Shoulder and Elbow Surgeons. Please the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Anatomic total shoulder arthroplasty with an inlay glenoid component and a stemless, ovoid humeral head led to a high rate of return to occupational and sporting activities and improved clinical outcomes, according to published results. Gregory P. Nicholson Gregory P. Nicholson, MD, an associate professor in the department of orthopedic surgery at Rush University Medical Center, and colleagues analyzed information for 27 shoulders in a retrospective review of total shoulder arthroplasty (TSA) with an inlay glenoid component, specifically in young, active patients with a minimum 2-year follow-up. “We know that traditional TSA in younger patients – just like hip and knee replacement – has a higher, earlier failure rate,” Nicholson told Healio Orthopedics. “This younger, active population is typically still in the workforce and has higher recreational activity levels that they don’t want to give up.” “In this higher activity level and younger population, I attempted to avoid the onlay failure by utilizing the best material combination of metal and plastic,” Nicholson said. “The Arthrosurface OVO with inlay glenoid is a modern TSA with two important features: The glenoid is inlayed into the subchondral bone level of the glenoid face, and the humeral head component is aspherical or ovoid shaped. This is closer to normal anatomy and has been shown to biomechanically transmit force across the glenoid less than traditional spherical heads.” “The system is bone sparing, has numerous biomechanical advantages, and the ‘symbiotic’ relationship between the inlay glenoid component and the subchondral surface bone provides excellent pain relief, range of motion, and return to work and recreational activity,” Nicholson added. The results showed significant improvements in patient-reported outcome measures and range of motion with no reoperations, according to the study abstract. The rate of return to work was 92.6%, with 76% of patients making a full recovery back to preoperative occupational demand levels. Results showed 92.59% of patients returned to work after undergoing total shoulder arthroplasty with an inlay glenoid component. “I think [the results] will stimulate more investigation on the kinematics of these types of TSA procedures with inlay glenoid components and the potential advantage of an aspherical humeral head shape,” Nicholson said. “There is another option to traditional stemmed TSA that can provide consistent pain relief, functional return and allow a higher activity level. This can allow patients of all walks of life to maintain a livelihood they may not have been able to continue with otherwise,” he added.

ArthroSurface Frequently Asked Questions (FAQ)

  • When was ArthroSurface founded?

    ArthroSurface was founded in 2002.

  • Where is ArthroSurface's headquarters?

    ArthroSurface's headquarters is located at 28 Forge Parkway, Franklin.

  • What is ArthroSurface's latest funding round?

    ArthroSurface's latest funding round is Acquired.

  • How much did ArthroSurface raise?

    ArthroSurface raised a total of $33.8M.

  • Who are the investors of ArthroSurface?

    Investors of ArthroSurface include Anika Therapeutics, Boston Millennia Partners and Primo Medical Group.

  • Who are ArthroSurface's competitors?

    Competitors of ArthroSurface include NeoChord, OrthAlign, Diamorph, SOLX, LDR Holding and 12 more.

Compare ArthroSurface to Competitors

F
Formae

Formae, Inc. Formae is developing new approaches to cartilage replacement for osteoarthritis, using hydrogels that closely mimic the mechanical properties of hyaline cartilage. Formae's approach is in that it is minimally invasive and aims to provide for total rather than focal joint resurfacing. The company has a broad portfolio of issued and pending patents and a well-defined product and regulatory strategy. The technology can be applied to any joint, and has the potential to be implanted arthroscopically. Following the completion of ex-vivo mechanical testing that will meet a critical regulatory milestone, Formae will be seeking funds to conduct in-vivo implantation and biocompatibility testing. .

A
Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

R
Ranier Technology

CAdisc is a unique, entirely polymeric Total Disc Replacement system for the treatment of degenerative disc disease in the lumbar and cervical spine. CAdisc-Lchar(2122) is designed to relieve pain and restore physiological quality of motion in the lumbar spine.

D
Dental Implants

Dental Implant Technologies (DIT) is a San Antonio based dental technology company providing an end to end suite of integrated implant based restorative services and products for dental patients requiring the replacement of most or all of their teeth. In the United States alone this market includes 30M individuals or a served addressable market of $96B including $26B for DIT's products and services.

S
Satiety

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

IntraOp Medical Logo
IntraOp Medical

IntraOp Medical Corporation provides ] technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms and has been used to treat over 20 different cancer indications. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and happier patients with fewer side effects. Leading hospitals and clinics throughout the world use the Mobetron as a vital part of their comprehensive cancer program.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.